Larimar Therapeutics (LRMR) Profit After Tax (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Profit After Tax for 14 consecutive years, with -$32.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 24.98% year-over-year to -$32.8 million; the trailing twelve-month figure through Jun 2026 stood at -$169.3 million (down 69.56% YoY), and the FY2025 full-year result was -$165.8 million, down 105.66% from the prior year.
• Profit After Tax advanced to -$32.8 million in Q2 2026 per LRMR's latest filing, from -$62.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$6.5 million in Q1 2023 and bottomed at -$62.5 million in Q4 2025.
• Historically, Profit After Tax has averaged -$20.7 million across 5 years, with a median of -$14.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax jumped 50.49% in 2022, then tumbled 207.84% in 2025.
• Over 5 years, Profit After Tax stood at -$9.4 million in 2022, then slumped by 37.32% to -$12.9 million in 2023, then plunged by 122.44% to -$28.8 million in 2024, then plunged by 117.02% to -$62.5 million in 2025, then soared by 47.53% to -$32.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$32.8 million, -$62.5 million, and -$47.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.